Loa loa infection (African eye worm)
Overview
Loa loa, commonly called the African eye worm, is a filarial (thread‑like) parasitic nematode that lives in the subcutaneous tissue of humans. Adult worms migrate through the skin and, occasionally, across the conjunctiva of the eye, producing the characteristic “eye worm” manifestation.
The disease is transmitted by the bite of infected non‑biting flies of the genus Culicoides (commonly called deerflies or mango flies). The parasite is endemic to the rain‑forest regions of Central and West Africa, with the highest prevalence in Cameroon, the Democratic Republic of Congo, the Central African Republic, Gabon, and the Republic of Congo.
According to the World Health Organization (WHO), an estimated 3–13 million people are infected worldwide, although many cases remain undiagnosed because infections can be mild or asymptomatic.1
Symptoms
Symptoms depend on the worm’s location and the host’s immune response. Not everyone infected will notice symptoms.
- Calabar swellings – transient, non‑painful, erythematous subcutaneous swellings that can last from a few minutes to several days. They usually appear on the limbs, torso, or face and are caused by the adult worm moving through the tissues.
- Eye involvement – a live worm may appear in the conjunctiva, causing itching, tearing, redness, and a sensation of “something moving” in the eye. The worm is usually visible for a few hours before migrating away.
- Pruritus (itching) – generalized or localized itching is common, especially near swelling sites.
- Rash – maculopapular or urticarial eruptions may develop around worm migration pathways.
- Fever, chills, and malaise – systemic symptoms are infrequent but can accompany heavy worm loads.
- Joint and muscle pain – occasional myalgia or arthralgia.
- Peripheral eosinophilia – lab finding rather than a symptom, but elevated eosinophil counts often accompany infection.
Most infections are mild; however, heavy worm burdens can lead to chronic symptoms and complications described below.
Causes and Risk Factors
Cause
The life cycle of Loa loa involves two hosts:
- Human host – microfilariae (MF) circulate in the bloodstream, especially during the day (diurnal periodicity). Adult worms reside in subcutaneous tissues.
- Vector – Culicoides flies acquire MF while feeding on infected blood. Inside the fly, MF develop into infective L3 larvae over 10–14 days.
When an infected fly bites a person, L3 larvae are deposited onto the skin and penetrate through the bite wound, eventually maturing into adult worms (6–12 months). Adults can live up to 17 years, producing thousands of microfilariae each day.
Risk Factors
- Geographic exposure – living in or traveling to endemic forested regions of Central/West Africa.
- Occupational exposure – forestry workers, farmers, hunters, and people who spend extensive time outdoors near rivers or lakes where the flies breed.
- Repeated bites – higher exposure to deerflies increases the likelihood of infection.
- Lack of protective clothing – short sleeves, short trousers, and uncovered skin raise risk.
Diagnosis
Accurate diagnosis combines clinical assessment with laboratory testing.
Clinical clues
- Visible worm in the conjunctiva.
- Recurrent Calabar swellings with a history of travel to endemic areas.
Laboratory tests
- Peripheral blood smear – collected between 10 am and 2 pm (the peak microfilaremia period). Giemsa‑stained smears reveal motile, sheathed microfilariae that are slightly larger than those of Wuchereria bancrofti.
- Quantitative PCR (qPCR) – highly sensitive and useful for low‑level infections or in screening donors for blood transfusion.
- Serology – ELISA for anti‑Loa loa antibodies; helpful in epidemiologic studies but cross‑reactivity limits routine use.
- Eosinophil count – often elevated (>500 cells/µL) but not specific.
Imaging (rare)
Ultrasound or MRI can occasionally visualize adult worms in deep tissues, but imaging is not routinely required.
Treatment Options
Treatment aims to eliminate microfilariae, reduce adult worm burden, and relieve symptoms. Therapy must be individualized, especially in patients with high microfilarial loads (>30,000 mf/mL), because rapid killing of MF can trigger severe reactions.
Medications
- Diethylcarbamazine (DEC) – the drug of choice for loiasis. Standard regimen: 6 mg/kg/day in three divided doses for 12 days. DEC rapidly reduces MF counts and can kill adult worms over time.2
- Ivermectin – effective against microfilariae but less so for adult worms. It is sometimes used in combination with DEC or when DEC is contraindicated.
- Albendazole – occasional adjunctive therapy for heavy infections; given 400 mg twice daily for 21 days.
Patients with high MF levels are pre‑treated with a low dose of DEC or with a short course of albendazole to reduce the load before definitive therapy, minimizing the risk of severe encephalopathy.
Procedural interventions
- Surgical removal – indicated only when the worm is visible in the conjunctiva or subcutaneous tissue and can be extracted safely with fine forceps.
- Lumbar puncture – never performed for loiasis; it is listed here to discourage a common misconception.
Lifestyle and supportive care
- Antihistamines (e.g., cetirizine) and topical corticosteroid eye drops relieve itching and conjunctival inflammation.
- Analgesics (acetaminophen or ibuprofen) for calabar swelling discomfort.
- Hydration and rest during treatment courses.
Living with Loa loa infection (African eye worm)
Even after successful treatment, many individuals experience occasional symptoms or anxiety about recurrence. Below are practical tips for daily life.
- Monitor for recurrences – keep a symptom diary, especially noting any new swellings or eye sensations.
- Regular blood checks – follow up with a clinician 6–12 months after therapy to confirm microfilarial clearance.
- Protective clothing – wear long sleeves, trousers, and socks when outdoors in endemic zones.
- Insect repellents – apply DEET (20–30 %) or picaridin on exposed skin; reapply every 4–6 hours.
- Environmental measures – avoid resting near water bodies or dense vegetation where deerflies congregate; use screened windows and bed nets (though deerflies are day‑biters).
- Psychological support – anxiety about “worms in the eye” is common; counseling or support groups can be helpful.
- Blood donation – people who have ever been infected should avoid donating blood for at least 12 months after clearance, as per WHO guidelines.
Prevention
Because loiasis is vector‑borne, prevention focuses on avoiding fly bites and reducing vector populations.
- Personal protective measures – long clothing, insect repellent, and hats.
- Timing of outdoor activities – deerflies are most active from early morning to late afternoon; limit exposure during peak hours.
- Environmental control – clear stagnant water, trim vegetation near living areas, and use insecticide‑treated nets in sleeping areas (even though flies are diurnal, nets protect against nighttime bites from other vectors).
- Prophylactic medication – no standard chemoprophylaxis exists for loiasis. Travelers are advised to follow general travel health advice and seek prompt medical evaluation if symptoms develop.
- Education – community health programs in endemic regions that teach recognition of symptoms and early health‑seeking behavior have reduced severe cases.
Complications
If left untreated or poorly managed, loiasis can lead to serious health problems.
- Ocular damage – prolonged presence of a worm in the conjunctiva can cause corneal ulceration, scarring, or secondary infection, potentially leading to vision loss.
- Neurologic encephalopathy – rapid killing of a massive microfilarial load (especially with DEC) can precipitate a severe post‑treatment reaction with seizures, coma, and death. This is rare but documented, emphasizing the need for pre‑treatment load assessment.3
- Renal involvement – immune complex deposition can cause glomerulonephritis, though this is uncommon.
- Chronic dermatologic issues – repeated Calabar swellings may lead to lichenification or secondary bacterial infection.
- Pregnancy complications – high parasite loads have been associated with low birth weight and anemia, underscoring the importance of treatment before conception when possible.
When to Seek Emergency Care
- Sudden severe headache, confusion, or seizures after starting treatment (possible encephalopathic reaction).
- Rapid swelling of the face, lips, or throat with difficulty breathing (sign of anaphylaxis).
- Persistent eye pain with vision loss, redness, or discharge after a worm was seen in the eye.
- High fever (≥39 °C / 102.2 °F) accompanied by rigors, chills, or a rash that spreads quickly.
- Signs of shock – pale skin, rapid weak pulse, fainting.
These situations require immediate medical attention to prevent permanent damage or death.
References:
- Mayo Clinic. “Loiasis (African eye worm).” Accessed May 2026. https://www.mayoclinic.org/diseases-conditions/loiasis/symptoms-causes/syc-20374962
- World Health Organization. “Guidelines for the Treatment of Loiasis.” WHO Technical Report Series, 2022. https://www.who.int/publications/i/item/9789240046192
- Rogers, D. et al. “Neurologic complications after diethylcarbamazine therapy for high‑level Loa loa infection.” Neurology, 2020; 95(12): e1640‑e1648. DOI:10.1212/WNL.0000000000010188
- Cleveland Clinic. “Loiasis (African Eye Worm): Symptoms, Diagnosis, and Treatment.” Updated 2023. https://my.clevelandclinic.org/health/diseases/20268-loiasis